oral CFTR ABC transporter potentiator

Ph. II for cystic fibrosis (5-80 mg QD), discont.

similarity screen of 589 cmpds + scaffold hop

J. Med. Chem., Jan. 5, 2021

Galapagos NV, Mechelen, BE

Structure of the Galapagos CFTR potentiator - GLPG2451

The Galapagos CFTR potentiator, GLPG2451, is an oral, once-daily clinical candidate for cystic fibrosis (5-80 mg QD). It was advanced into a high-profile Ph. II triple-combo study with the…

get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: